DESCRIPTION: (Applicant's Abstract)
When an abused drug is self-administered it produces internal stimuli in the
user of which the user is often aware. We refer to these effects in humans
as the "subjective effects" of the drug. One way in which behavioral
pharmacologists have studied these internal stimuli in animal models has
been to establish them as discriminative stimuli. Responses can be
scheduled to occur or not occur in the presence or absence of these internal
drug stimuli by differentially reinforcing responding. These drug
discrimination procedures have been used to study the behavioral
consequences of a number of effects of drugs at the cellular level of the
brain including receptor binding, neurotransmitter depletion, and many
others. Despite the widespread usage of drug discrimination procedures,
there are many questions about the procedure that have not been answered.
For example, there are arguments about whether or not drug discrimination
gradients are quantal or graded. It is not known if the discrimination
between two different drugs differs from the discrimination between the
presence and absence of a single drug. Although the experience of an
organism with other drugs has been shown to be an important determinant of
many drug effects, such historical factors have received little attention in
drug-discrimination research. The ability of animals to learn complex drug
discriminations has also received little attention and there are almost no
studies in the literature that systematically compare the effects of drugs
as discriminative stimuli with their effects on other behaviors. The
proposed research would fill this gap by determining how reinforcement
schedules and drug discrimination training history affect the discriminative
stimulus properties of drugs. Experiments would also be conducted to
develop new procedures for studying and interpreting complex drug
discriminations and for comparing the effects of drugs as discriminative
stimuli to their effects on animal models of anxiety, memory and other
important behaviors. These experiments will provide fundamental new
information about the drug discrimination process that should greatly add to
our knowledge of how the stimulus properties of drugs contribute to their
abuse.
Public Health Relevance Statement
Data not available.
NIH Spending Category
No NIH Spending Category available.
Project Terms
central nervous system depressantschronic disease /disorderdiscrimination learningdrug abusedrug interactionslaboratory ratmemorypigeonspsychomotor functionpsychopharmacologyreinforcerspecies differencestimulant /agonist
No Sub Projects information available for 2R01DA002251-18A1
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 2R01DA002251-18A1
Patents
No Patents information available for 2R01DA002251-18A1
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 2R01DA002251-18A1
Clinical Studies
No Clinical Studies information available for 2R01DA002251-18A1
News and More
Related News Releases
No news release information available for 2R01DA002251-18A1
History
No Historical information available for 2R01DA002251-18A1
Similar Projects
No Similar Projects information available for 2R01DA002251-18A1